Sign in or Register   Sign in or Register
  |  

Mouse Anti-ITM2B Recombinant Antibody (1C11) (CBMAB-1591-CN)

This product is a mouse antibody that recognizes ITM2B of human. The antibody 1C11 can be used for immunoassay techniques such as: FC, IHC-P, WB.
See all ITM2B antibodies

Summary

Host Animal
Mouse
Specificity
Human
Clone
1C11
Antibody Isotype
IgG2a
Application
FC, IHC-P, WB

Basic Information

Immunogen
Recombinant full length Human ITM2B produced in HEK293T cells (NP_068839)
Specificity
Human
Antibody Isotype
IgG2a
Clonality
Monoclonal
Application Notes
The COA includes recommended starting dilutions, optimal dilutions should be determined by the end user.

Formulations & Storage [For reference only, actual COA shall prevail!]

Format
Liquid
Buffer
1% BSA, 50% Glycerol, 48% PBS, pH 7.3
Preservative
0.02% Sodium azide
Concentration
1 mg/mL
Storage
Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.

Target

Full Name
integral membrane protein 2B
Introduction
Amyloid precursor proteins are processed by beta-secretase and gamma-secretase to produce beta-amyloid peptides which form the characteristic plaques of Alzheimer disease. This gene encodes a transmembrane protein which is processed at the C-terminus by furin or furin-like proteases to produce a small secreted peptide which inhibits the deposition of beta-amyloid. This protein plays a regulatory role in the processing of the amyloid-beta A4 precursor protein (APP) and acts as an inhibitor of the amyloid-beta peptide aggregation and fibrils deposition.
Entrez Gene ID
9445
UniProt ID
Q9Y287
Alternative Names
BRI; FBD; ABRI; BRI2; E25B; E3-16; RDGCA; imBRI2; BRICD2B
Function
Plays a regulatory role in the processing of the amyloid-beta A4 precursor protein (APP) and acts as an inhibitor of the amyloid-beta peptide aggregation and fibrils deposition. Plays a role in the induction of neurite outgrowth. Functions as a protease inhibitor by blocking access of secretases to APP cleavage sites.
Mature BRI2 (mBRI2) functions as a modulator of the amyloid-beta A4 precursor protein (APP) processing leading to a strong reduction in the secretion of secretase-processed amyloid-beta protein 40 and amyloid-beta protein 42.
Bri23 peptide prevents aggregation of APP amyloid-beta protein 42 into toxic oligomers.
Biological Process
Negative regulation of amyloid precursor protein biosynthetic processManual Assertion Based On ExperimentIDA:UniProtKB
Nervous system developmentManual Assertion Based On ExperimentTAS:ProtInc
Cellular Location
Integral membrane protein 2B: Golgi apparatus membrane. Immature BRI2 (imBRI2) is cleaved by furin in the Golgi into mBRI2 and a Bri23 peptide. mBRI2 is transported to the plasma membrane and Bri23 peptide is secreted.
BRI2, membrane form: Cell membrane; Endosome membrane. Mature BRI2 (mBRI2) needs to be transported from the endoplasmic reticulum compartment to the cell membrane in order to be able to inhibit APP processing.
Bri23 peptide: Secreted. Detected in the cerebral spinal fluid (CSF).
BRI2C, soluble form: Secreted
Involvement in disease
Cerebral amyloid angiopathy, ITM2B-related 1 (CAA-ITM2B1):
A disorder characterized by amyloid deposition in the walls of cerebral blood vessels and neurodegeneration in the central nervous system. Cerebral amyloid angiopathy, non-neuritic and perivascular plaques and neurofibrillary tangles are the predominant pathological lesions. Clinical features include progressive mental deterioration, spasticity and muscular rigidity.
Cerebral amyloid angiopathy, ITM2B-related 2 (CAA-ITM2B2):
A disorder characterized by amyloid deposition in the walls of the blood vessels of the cerebrum, choroid plexus, cerebellum, spinal cord and retina. Plaques and neurofibrillary tangles are observed in the hippocampus. Clinical features include progressive ataxia, dementia, cataracts and deafness.
Retinal dystrophy with inner retinal dysfunction and ganglion cell abnormalities (RDGCA):
An autosomal dominant retinal dystrophy characterized by inner retinal dysfunction in association with ganglion cell abnormalities. Clinical features include mild photophobia, progressive loss of central vision, night blindness, and hyperreflectivity of nerve and ganglion cell layers.
Topology
Cytoplasmic: 1-54
Helical: 55-75
Lumenal: 76-266
PTM
The ectodomain C-terminal part of the imBRI2 is processed by furin producing a secreted Bri23 peptide and a mature BRI2, membrane form (mBRI2). The remaining part of the ectodomain of mBRI2 containing the BRICHOS domain is cleaved by ADAM10 and is secreted (BRI2C, soluble form). The membrane-bound N-terminal fragment (BRI2C, membrane form) is further proteolytically processed by SPPL2A and SPPL2B through regulated intramembrane proteolysis producing a secreted C-peptide and a BRI2 intracellular domain (BRI2 ICD) released in the cytosol. Shedding by ADAM10 facilitates intramembrane cleavage but is not absolutely required for BRI2 ICD generation.
Glycosylation at Asn-170 is important for cell surface localization, but doesn't affect furin- and ADAM10-induced proteolytic processing.

Rhyu, J. M., Park, J., Shin, B. S., Kim, Y. E., Kim, E. J., Kim, K. W., & Cho, Y. G. (2023). A Novel c. 800G> C Variant of the ITM2B Gene in Familial Korean Dementia. Journal of Alzheimer's Disease, (Preprint), 1-7.

Letellier, C., Wohlschlegel, J., Condroyer, C., Slembrouck-Brec, A., Goureau, O., Zeitz, C., & Audo, I. (2023). Generation of gene corrected human isogenic iPSC lines (IDVi003-A_CR13, IDVi003-A_CR21, IDVi003-A_CR24) from an inherited retinal dystrophy patient-derived IPSC line ITM2B-5286-3 (IDVi003-A) carrying the ITM2B c. 782A> C variant using CRISPR/Cas9. Stem Cell Research, 71, 103166.

Nassisi, M., Wohlschlegel, J., Liu, B., Letellier, C., Michiels, C., Aubois, A., ... & Audo, I. (2021). Deep phenotyping and further insights into Itm2b-related retinal dystrophy. Retina, 41(4), 872-881.

Liu, X., Chen, K. L., Wang, Y., Huang, Y. Y., Chen, S. D., Dong, Q., ... & Yu, J. T. (2021). A novel ITM2B mutation associated with familial Chinese dementia. Journal of Alzheimer's Disease, 81(2), 499-505.

Yin, T., Yao, W., Lemenze, A. D., & D’Adamio, L. (2021). Danish and British dementia ITM2b/BRI2 mutations reduce BRI2 protein stability and impair glutamatergic synaptic transmission. Journal of Biological Chemistry, 296.

Wohlschlegel, J., Argentini, M., Michiels, C., Letellier, C., Forster, V., Condroyer, C., ... & Audo, I. (2021). First identification of ITM2B interactome in the human retina. Scientific Reports, 11(1), 17210.

Zhou, J. H., Yao, Z. X., Zheng, Z., Yang, J., Wang, R., Fu, S. J., ... & Wu, K. (2020). G-MDSCs-derived exosomal miRNA-143-3p promotes proliferation via targeting of ITM2B in lung cancer. OncoTargets and therapy, 9701-9719.

Jiang, Y., Jiao, B., Liao, X., Xiao, X., Liu, X., & Shen, L. (2020). Analyses Mutations in GSN, CST3, TTR, and ITM2B Genes in Chinese Patients With Alzheimer’s Disease. Frontiers in aging neuroscience, 12, 581524.

Yao, W., Yin, T., Tambini, M. D., & D’Adamio, L. (2019). The Familial dementia gene ITM2b/BRI2 facilitates glutamate transmission via both presynaptic and postsynaptic mechanisms. Scientific reports, 9(1), 4862.

Mandal, A. K., & Mount, D. B. (2019). Interaction between ITM2B and GLUT9 links urate transport to neurodegenerative disorders. Frontiers in physiology, 10, 1323.

Ask a question We look forward to hearing from you.
0 reviews or Q&As

Purchasing FAQs
Technical FAQs

Loading...
Have you used Mouse Anti-ITM2B Recombinant Antibody (1C11)?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon $30 eGift Card
Submit a review
Loading...
For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Online Inquiry

Documents

Contact us

  • Tel: (USA)
  • (UK)
  • Fax:
  • Email:

Submit A Review

Go to
Compare